Peptides with improved properties having the biological activity of vasoactive intestinal peptide (VIP) and their use for the treatment of lung diseases
The present invention relates to novel peptides that are highly biologically and pharmacologically active as therapeutic agents for the treatment of numerous lung diseases or lung and/or bronchi related diseases, especially chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and Bronchiolitis obliterans (BO). The synthetic peptides according to the invention are derivatives of vasoactive intestinal peptide (VIP) and show enhanced physical, pharmacological and biological/therapeutic properties compared to VIP.
